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Non-thromboembolic risk in systemic lupus erythematosus
associated with antiphospholipid syndrome
M Dea´k, M Bocskai, S Burcsa´r, O Da´nyi, Z Fekete and L Kova´cs
Department of Rheumatology, University of Szeged, Faculty of Medicine, Albert Szent-Gyo¨rgyi Health Centre, Szeged, Hungary
Objectives: We investigated the impact of secondary antiphospholipid syndrome (APS) and
antiphospholipid antibody (aPL) positivity on the non-thromboembolic clinical manifest-
ations of systemic lupus erythematosus (SLE). Methods: In total, 224 patients with SLE
were studied, of whom 105 were aPL-positive; 52 fulfilled the criteria for APS. SLE- and
APS-related clinical and laboratory features were assesed: SLE patients with aPL or APS were
compared with those without these features. Results: Not only thromboembolic events, but
also Coombs-positive haemolytic anaemia, thrombocytopenia and endocarditis occurred sig-
nificantly more frequently in the aPL-positive than in the aPL-negative patients. In the
APSþ SLE subgroup, several non-thromboembolic symptoms occurred more often than in
the absence of APS: pleuritis, interstitial lung disease, myocarditis, nephritis and organic brain
syndrome. The mean number of major organ manifestations (1.2 vs. 0.5) and the overall
number of organ manifestations (8.1 vs. 6.9) were higher in the APSþ SLE patients than in
those without APS (p< 0.05). The APSþ SLE subgroup more frequently required intensive
immunosuppressive treatment than did the APS-negative patients (p< 0.05). Conclusions:
SLE patients with aPL positivity or secondary APS also have a higher risk to develop non-
thromboembolic disease manifestations in addition to the aPL-related symptoms, and are
predisposed to more severe SLE manifestations. Lupus (2014) 0, 1–6.
Key words: Systemic lupus erythematosus; secondary antiphospholipid syndrome; non-throm-
boembolic risk; lupus anticoagulant; antiphospholipid autoantibodies
Introduction
Systemic lupus erythematosus (SLE) is a heteroge-
neous systemic autoimmune disease, characterized
by immune-mediated inﬂammation in multiple
organs. The course of the disease is tipiﬁed by
exacerbations and remissions, and the severity of
the clinical picture is greatly aﬀected by the
number and nature of the various organ manifest-
ations. The mortality in patients with SLE is still
considerable, and it may be due to lupus activity,
when vital organs are involved; the complications
of treatment, in particular infections; or to long-
term complications, such as cardiovascular
disorders.1,2
Typically, patients with SLE produce numerous
autoantibodies. Some of the SLE-related
autoantibodies, e.g. anti-dsDNA, correlate with
disease activity, while others appear to be markers
of speciﬁc disease subsets (e.g. anti-Ro/SSA); more-
over, the presence of antiphospholipid antibodies
(aPLs) is deﬁnitely pathogenic.3,4 aPL positivity
itself predisposes to accelerated atherosclerosis
and to an increased thromboembolic risk.5–7
The aPLs form a heterogeneous group of auto-
antibodies, including lupus anticoagulant (LA),
anti-cardiolipin (aCL) and anti-beta2-glycoprotein
I (ab2GPI). The latter two antibodies can be pre-
sent in IgG, IgM and IgA isoforms, and are dir-
ected against anionic membrane phospholipids and
associated proteins, and the IgG isotypes in par-
ticular are of clinical signiﬁcance.6,8,9 The reported
prevalence of aPL in SLE varies between 15 and
35%.10–13
In the antiphospholipid syndrome (APS), the
production of aPLs is accompanied by arterial or
venous thrombotic events, or an adverse pregnancy
outcome.14–16 APS can be a primary, independent
entity, but also presents as a secondary feature in
malignant processes, autoimmune diseases or
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following infections. APS is frequently associated
with SLE, and this association leads to hypercoa-
gulability and speciﬁc vaso-occlusive, ischaemic
lesions. In addition, particular clinical features,
such as thrombocytopenia, Coombs-positive hae-
molitic anaemia, Raynaud’s phenomenon, livedo
reticularis and non-bacterial endocarditis have
been found to be more common in SLE with sec-
ondary APS than in SLE without this associ-
ation.16,17 APS is also a major predictor of
irreversible organ damage and death in patients
with SLE,17 in part because cardiovascular diseases
cause a substantial morbidity.
Objectives
In view of the heterogeneity of SLE, it is important
to identify prognostic clinical, demographic and
laboratory parameters that would facilitate the pre-
diction of the disease outcome in a condition in
which an apporopriate early assessment and risk
stratiﬁcation are crucial to prevent life-threatening
complications and to decide on the appropriate
treatment, including immunosuppressive agents.
Certain demographic parameters (e.g. age at
onset, gender, etc.)18–23 and speciﬁc autoantibody
positivities24–27 have been found useful in reaching
prognostic conclusions. It is well known that the
presence of aPLs is of strong predictive value in
the development of various micro- and macrovas-
cular organ involvements in which acute or chronic
thrombotic mechanisms are key pathogenetic fac-
tors.7,8,28 However, there are no data in the litera-
ture as to whether aPL-positive patients are
predisposed to other non-thrombotic SLE-related
morbidities.
Our present aim was therefore to study the
impacts of aPL positivity alone and secondary
APS on the clinical presentation of SLE. We
investigated whether certain non-thrombotic SLE
manifestations appear more frequently in the sub-
groups of patients with aPL production and
deﬁnitive APS, and assessed the diﬀerences in dis-
ease severity and progression and the therapeutic
requirements in these subgroups as compared with
aPL-negative or APS-negative SLE patients,
respectively.
Patients and methods
We performed a retrospective study on consecutive,
unselected adult (age> 18 years) patients with SLE
attending the Department of Rheumatology,
Faculty of Medicine at University of Szeged,
Hungary. In total, 224 patients were enrolled, all
of whom fulﬁlled the American College of
Rheumatology criteria for the classiﬁcation of
SLE.29,30 The proportion of female patients was
91% (n¼ 204), and the mean age of the patients
at the time of inclusion was 49 (20–92) years,
while the average length of time since the diagnosis
was established was 13 (0–49) years.
The diagnosis of APS was based on the Sydney
criteria.31 aPL-s were considered positive when at
least two determinations 12 weeks apart were posi-
tive for LA or aCL or ab2GPI IgG and/or IgM.
The diagnosis of APS required aPL positivity coex-
isting with documented obstetric and/or throm-
botic complications.
Various SLE- and APS-related clinical and
laboratory features were compared between
patients without or with aPL positivity. The data
on the SLEþAPS patients were also compared
with those on the SLE patients without APS. The
parameters were studied in three categories, relat-
ing to organ involvement, laboratory parameters
and immunosuppressive therapy.
Organ involvement
In this study 31 types of organ involvements of SLE
were included. The manifestations involving the
heart, the lungs, the kidneys and the central ner-
vous system were regarded as major organ mani-
festations, as these have a profound impact on the
outcome of the disease. The diagnosis of the vari-
ous lupus-related organ involvements was estab-
lished on standard clinical methods, radiological
or histological signs. Other causes of organ
damage or any other pathological condition, e.g.
drug- or infection-related symptoms, were
excluded. The deﬁnitions of selected organ mani-
festations were as follows.
Nephritis was recorded in the event of biopsy-
proven lupus glomerulonephritis exhibiting a
characteristic histological picture (class I–V lupus
nephritis) or, if a biopsy was not performed, the
presence of proteinuria 0.5 g/d and/or micro-
scopic hematuria and/or cylindruria not explained
by any condition other than active SLE.
Pulmonary involvement was diagnosed when
speciﬁc signs of parenchymal lung disease, includ-
ing interstitial pneumonitis, chronic ﬁbrosing alve-
olitis (pulmonary ﬁbrosis) or acute alveolitis were
demonstrated by radiological examination.
Organic brain syndrome denoted diﬀuse brain
tissue damage with psycho-organic syndrome.
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Skin vasculitis included the clinical presence of
cutaneous vasculitis including periungual vasculitis,
digital vasculitis, nodular vasculitis, livedo vascu-
litis, urticaria vasculitis, purpura or crural ulcers,
in selected cases veriﬁed by histological
examination.
Neuropathy comprised cranial and peripheral
inﬂammatory neuropathies.
Secondary Sjo¨gren’s syndrome was regarded in
the presence of objective and subjective sicca symp-
toms aﬀecting the eyes and/or the mouth, with
decreased tear and/or saliva production, meeting
the American-European Consensus Criteria for
Sjo¨gren’s syndrome.32
Laboratory tests
Laboratory variables related to SLE were evalu-
ated, including haemolytic and non-haemolytic
anaemia (haematocrit< 35%), leukopenia
(WBC< 4.0G/l), lymphopenia (Ly< 1.5G/l) and
thrombocytopenia (Thr< 100G/l). Haemolysis
was veriﬁed with Coombs test and increased reticu-
locyte count, whereas non-haemolytic anaemia
comprised anaemia due to chronic inﬂammation
or lupus-related myelopathy, but other causes,
including occult gastrointestinal blood loss, antic-
oagulation-related gynaecological blood loss,
chronic renal failure, etc. were not recorded as
lupus-related anaemia. The immunoserological
proﬁle of the patients was also assessed: anti-
nuclear antibody (ANA), anti-dsDNA, anti-SSA,
anti-SSB, anti-Sm, anti-RNP, aCL, ab2GPI, LA
and hypocomplementaemia (C3 and C4) were
examined. The tests were performed at the
Department of Laboratory Medicine of our
University by means of routine diagnostic methods
(ELISA, nephelometry, LA-sensitive coagulation
tests, etc.).
Immunosuppressive therapy
Depending on the severity of the disease, milder
(e.g. chloroquine) or more potent immunomodula-
tory agents (eg. cyclophosphamide) were adminis-
tered based upon the decision of the treating
physician. Treatment with oral or i.v. corticoster-
oid, chloroquine, azathioprine, methotrexate,
cyclosporine or i.v. cyclophosphamide was rec-
orded in detail.
Statistical methods
The diﬀerences between the occurrence of the vari-
ous organ manifestations, the immunoserological
variables and the diﬀerent treatment modes in the
various subgroups were calculated with the chi2
test. Levels p< 0.05 were regarded as statistically
signiﬁcant.
Results
The most common clinical manifestations, immu-
noserological abnormalities and immunosuppres-
sive therapies in the overall cohort can be seen in
Table 1. The frequency of the distinct aPLs ranged
between 20 and 33%. Of the patients, 105 (47%)
were found to produce at least one type of aPL,
according to the Sidney criteria, and 52 of these
aPL-positive patients (23% of the total) fulﬁlled
the criteria for APS (Figure 1). The APS-related
clinical manifestations were venous thromboembol-
ism (39 patients), stroke (eight patients), and
repeated spontaneous abortion or intrauterine
death (nine patients).
The impact of antiphospholipid antibody positivity
Several clinical diﬀerences were detected between
the aPL-positive (n¼ 105) and negative patients
(n¼ 119). The data in Table 2 reveal that not only
venous thromboembolism, but also endocarditis,
haemolytic anaemia and thrombocytopenia were
observed nearly three times more often in the
aPL-positive patients than in those without aPLs.
Although endocarditis is a relatively rare manifest-
ation of SLE, it occurred exclusively in the
aPL-positive patients, supporting the role of aPL
positivity as a risk factor in the development of
non-bacterial endocarditis. The aPL-positive
patients exhibited a signiﬁcantly higher morbidity
than that for the aPL-negative patients, as indi-
cated by the signiﬁcantly higher total number of
organ involvements detected during the course of
the disease.
The clinical presentation of SLE with secondary
antiphospholipid syndrome
The frequency of APS among our patients is in
accord with the literature ﬁndings that 15–30% of
SLE cases are associated with APS.14,15,33
The disease course of the patients in whom SLE
was accompanied by secondary APS displayed sig-
niﬁcant clinical diﬀerences as compared with the
APS-negative SLE subgroup (Table 3). Patients
with APS exhibited major SLE manifestations
more frequently than did those patients without
secondary APS (average numbers per patient: 1.2
vs. 0.5; p< 0.05). Stroke, as a thrombotic event
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typically present in APS, was excluded from the
major manifestations in this comparison. APS
also proved to be accompanied by a higher total
number of organ involvements in comparison
with the aPL-negative patients (8.1 vs. 6.9;
p< 0.05), similarly to that seen in the cases with
aPL positivity alone. However, aPL positivity
alone did not lead to an increased incidence of
major SLE manifestations.
As is to be expected in APS, stroke, thrombo-
embolism and spontaneous abortion were more
common in this patient subgroup than in the
absence of APS. In addition, a signiﬁcantly higher
proportion of the APS cases than in the non-APS
group developed myocarditis, pleuritis, nephritis,
interstitial pulmonary involvement, organic brain
syndrome or thrombocytopenia (Table 3). Lupus
glomerulonephritis was present in more than half
of the SLEþAPS cases, and renal involvement is
known to be crucial in determining the outcome of
the disease.
The more severe disease course in APS implies
the need for more aggressive therapy. When SLE
was complicated by APS, the patients required i.v.
corticosteroid, cyclophosphamide, or azathioprine
medication signiﬁcantly more often (Table 3).
Discussion
SLE can present a wide variety of organ involve-
ments. The burden of the disease is even greater
Table 1 Prevalences of the most common and the major
clinical manifestations, the immunoserological abnormalities
and the immunosuppressive therapies in the studied SLE
patients
%
Arthritis 89.3
Photosensitivity 65.2
Non-haemolytic anaemia 56.3
Raynaud’s phenomenon 54.9
Leukopenia 54.0
Lymphopenia 46.0
Other skin manifestations 32.1
Lymphadenomegaly 31.3
Pleuritis 30.4
Pericarditis 24.1
Butterfly erythema 20.5
Thromboembolism 19.2
Skin vasculitis 18.8
Thrombocytopenia 17.9
Secondary Sjo¨gren’s syndrome 17.9
Haemolytic anaemia 14.7
Oral ulceration 10.3
Repeated spontaneous abortion 5.2*
Nephritis 35.3
Pulmonary involvement 8.9
Organic brain syndrome 7.1
Stroke 4.5
Myocarditis 3.6
Convulsion 3.6
Psychosis 2.7
Endocarditis 1.3
ANA 87.1
anti-dsDNA 76.3
anti-SSA 46.0
anti-SSB 33.9
anti-Sm 21.4
anti-RNP 16.1
anti-CL 35.3
anti-ß2GPI 23.2
LA 24.6
low C3 62.9
low C4 46.4
oral corticosteroid 90.2
i.v. corticosteroid 37.5
chloroquin 62.9
azathioprin 34.4
i.v. cyclophosphamide 25.9
methotrexate 21.0
cyclosporin A 9.8
SLE: systemic lupus erythematosus, aCL: anti-cardiolipin, anti-ß2GPI:
anti-beta2-glycoprotein I, LA: lupus anticoagulant, ANA: anti-nuclear
antibodies, anti-dsDNA: anti-double stranded DNA, anti-SSA: anti-
Sjo¨gren’s syndrome A, anti-SSB: anti-Sjo¨gren’s syndrome B, iv.:
intravenous,
Numbers indicate percentages. *in female patients
The major manifastations are written in bold.
APA-
53%
single
APA+
51%
APS
49%
APA+
47%
Figure 1 Proportions of aPL-positive, aPL-negative and APS
patient subgroups. aPL: antiphospholipid antibody, APS: anti-
phospholipid syndrome.
Table 2 Clinical differences between the APAþ and the
APA- SLE patients
Mean number
of total
organ
involvements
Endocarditis
%
Thrombo-
embolism %
Haemolytic
anaemia %
Thrombo-
cytopenia %
APAþ 7.6 2.8 29.5 21.9 25.7
APA 6.8 0 10.1 8.4 10.9
p <0.05 0.101 0.000 0.007 0.005
APA: antiphospholipid antibody, SLE: systemic lupus erythematosus.
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when major manifestations occur, e.g. exhibiting
central nervous system, cardiac, pulmonary and
renal symptoms. As the disease course is highly
variable, ranging from mild, intermittent symptoms
to life-endangering ﬂares or a frequently relapsing
clinical course, any parameter of predictive value
with regard to the severity of the disease is highly
informative for both the patient and the treating
physician. The presence of certain autoantibodies
can indicate an increased likelihood of various
organ manifestations. As examples, anti-C1q anti-
bodies are associated with the development of
nephritis,25 and anti-ribosomal-P antibodies with
neuropsychiatric SLE,26,27 and if these autoantibo-
dies are detected, close attention to the early recog-
nition of the development of these serious
manifestations may help prevent irreversible
organ damage. aPLs are particularly useful in the
prediction of thromboembolic events, and treat-
ment guidelines advocate preventive platelet aggre-
gation inhibitor therapy even without previous such
events.33,34 The presence of aPLs not only enhances
the thromboembolic risk and accelerates athero-
sclerosis,35 but has also been veriﬁed to be asso-
ciated with higher lupus-related organ damage17
and a poorer survival.2,17
Although the contribution of secondary APS to
the clinical picture of SLE with regard to APS-spe-
ciﬁc symptoms has been extensively studied, we
have not found any detailed analysis in the litera-
ture as concerns the impact of secondary APS on
other lupus-related clinical events. Our study has
revealed novel aspects of the disease course of
SLE combined with secondary APS. The results
highlighted several non-thromboembolic SLE
manifestations that present more frequently in rela-
tion to secondary APS. In accordance with earlier
literature data, a signiﬁcantly higher proportion of
the aPL-positive than of the aPL-negative SLE
patients developed Coombs-positive haemolytic
anaemia, thrombocytopenia or endocarditis.
Moreover, we found signiﬁcant diﬀerences in the
clinical presentation ofSLE when it was compli-
cated by APS, since various non-thromboembolic
symptoms, including pleuritis, interstitial lung dis-
ease, myocarditis, nephritis and organic brain syn-
drome, occurred more often than in the absence of
APS.
The presented results also proved that patients
with secondary APS are more predisposed to a
more severe SLE disease course. The total
number of major organ manifestations and the
total number of organ manifestations that had
ever occurred in an individual patient were both
higher in the SLEþAPS patients than in those
without APS. In contrast, aPL positivity alone
was only accompanied by an increased incidence
of organ involvements.
The treatment of active SLE itself is a challenge,
but the situation is further complicated by second-
ary APS. Our results conﬁrmed that in the presence
of APS, patients with SLE have a need not only for
long-term anticoagulant treatment, but also more
frequently require powerful immunosuppressive
therapy including i.v. corticosteroid, i.v. cyclophos-
phamide and azathioprine than the non-APS
patients (p< 0.05).
In conclusion, SLE patients with aPL positivity
or with secondary APS are at a higher risk of the
development of non-thromboembolic disease mani-
festations in addition to the aPL-related symptoms.
APS usually presents in young or middle-aged SLE
patients, and this is followed by a longer disease
course and enhanced disease severity, with a predis-
position to more extensive organ damage. These
results indicate that early screening for aPLs, at
the time of the diagnosis in SLE patients, is essen-
tial. The higher morbidity and mortality of these
patients requires extremely close control with the
aim of the early detection of potential nephritis,
interstitial lung disease or neuropsychiatric mani-
festations, with the provision of appropriate,
often intense immunosuppressive therapy that can
prevent life-threatening organ involvements and
complications.
Table 3 Differences in the frequency of selected organ
involvements and in the therapeutical requirements between
the SLEþAPS and SLEþ non-APS patients (p< 0.05)
SLEþAPS SLEþ non-APS
Stroke 15.4% 1.2%
Thromboembolism 75.0% 2.3%
Spontaneous abortion 17.3% 1.25%
Pleuritis 40.4% 24.3 %
Nephritis 53.9% 29.4%
Myocarditis 7.7% 2.3%
Pulmonary involvement 17.3% 6.4%
Organic brain syndrome 13.5% 5.2%
Thrombocytopenia 26.9% 17.8%
Total number of organ involvements
per patient
8.1 6.9
Total number of major organ involvements
per patient
1.2 0.5
iv. corticosteroid 56% 32%
azathioprine 52% 29%
cyclophosphamide 39% 22%
APS: antiphospholipid syndrome, SLE: systemic lupus erythematosus,
i.v: intravenous.
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